沙利度胺在口腔黏膜病临床治疗实践中的安全性分析
Analysis of the safety of thalidomide in the treatment of oral mucosal diseases

摘要： 沙利度胺诞生至今已经超过60年，目前广泛应用于炎症性疾病和自身免疫性疾病的治疗，包括多种口腔黏膜疾病的治疗。由于沙利度胺曾造成严重的致畸不良事件，所以较多医生对其在临床具体应用过程中的安全性尚存在一些疑问和顾虑。本文通过回顾分析有关沙利度胺的药物代谢动力学、药物作用机制以及临床治疗试验研究的文献，着重探讨沙利度胺的药物安全性、对育龄期患者的影响以及对儿童患者的影响等问题，以期为口腔黏膜病科医生提供更为全面的信息，确保其安全有效的应用。
Abstract: Thalidomide has been on the market for more than 60 years. It is currently used for the treatment of inflammatory and autoimmune diseases, including a variety of oral mucosal diseases. Due to its serious teratogenic effect, many oral medicine specialists are very cautious about the safety of thalidomide in the clinical application. To clarify its effect, especially on patients of childbearing age and children, we sum up the pharmacokinetics, mechanism and clinical studies of thalidomide. We hope that this review could provide oral medicine specialists with more comprehensive information on the clinical safety and effectiveness of thalidomide for the treatment of oral mucosal diseases.
中图分类号